Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCizzle Biotech Regulatory News (CIZ)

Share Price Information for Cizzle Biotech (CIZ)

Share Price is delayed by 15 minutes
Get Live Data
2.40    0.00 (0.00%)
Bid:
2.30
Ask:
2.50
Spread: 0.20 (8.696%)
Market Cap: £10.20m
CIZ Live PriceLast checked at - London Stock Exchange

Intraday Cizzle Biotech Share Chart

Holding(s) in Company

23 Apr 2024 11:20

RNS Number : 6981L
Cizzle Biotechnology Holdings PLC
23 April 2024
Β 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BNG2VN02

Issuer Name

Cizzle Biotechnology Holdings plc

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Alan Miller

City of registered office (if applicable)

London

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

Β 

City of registered office (if applicable)

Β 

Country of registered office (if applicable)

Β 

5. Date on which the threshold was crossed or reached

10-Apr-2024

6. Date on which Issuer notified

23-Apr-2024

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

4.250000

0.000000

4.250000

16858844

Position of previous notification (if applicable)

4.730000

0.000000

4.730000

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BNG2VN02

16858844

4.250000

Sub Total 8.A

16858844

4.250000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

Β 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

Β 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Β 

10. In case of proxy voting

Name of the proxy holder

Β 

The number and % of voting rights held

Β 

The date until which the voting rights will be held

Β 

11. Additional Information

Β 

12. Date of Completion

10-Apr-2024

13. Place Of Completion

London

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
HOLUOARRSKUSUAR
Date   Source Headline
16th Jun 202612:33 pmRNSResult of AGM
16th Jun 20267:00 amRNSCIZ1B Test Approved For Clinical Use in USA
12th Jun 20267:00 amRNSPatent Granted in USA
21st May 20267:51 amRNSNotice of AGM
7th May 20267:00 amRNSIssue of Options, Salary Waivers, Incentive Plan
6th May 20267:00 amRNSConversion of Convertible Loan Notes
30th Apr 20267:00 amRNSFinal results for the year ended 31 December 2025
2nd Apr 20267:00 amRNS£250,000 Funding Facility
23rd Feb 20267:00 amRNSProgress on Launch of Biomarker Test in USA
4th Feb 20267:00 amRNSPatent Granted in Canada
5th Nov 20257:01 amRNS£250,000 Convertible Loan Note Issue
5th Nov 20257:00 amRNSLOI with leading UK Clinical Diagnostic Group
27th Oct 202511:32 amRNSChange of Registered Office
30th Sep 20257:00 amRNSInterim Results
29th Sep 20257:00 amRNSUpdate on Clinical Laboratory Partnerships in USA
18th Aug 20257:00 amRNSCommercial Progress in USA
30th Jun 20251:45 pmRNSResult of AGM
6th Jun 202511:00 amRNSNotice of AGM
28th May 20257:00 amRNSHolding(s) in Company
20th May 20257:00 amRNS£150,000 Convertible Loan Note Issue
30th Apr 202511:18 amRNSFinal results for the year ended 31 December 2024
28th Apr 20257:00 amRNSContract in Caribbean and Update on CIZ1B
14th Apr 202510:00 amRNS-RLaunch of New Website
25th Mar 20257:00 amRNSAppointment of Non-Executive Director
24th Mar 20257:00 amRNSUpdate on Launch of CIZ1B Biomarker Assay
2nd Jan 20257:00 amRNSAppointment of Professor Dawn Coverley as CSO
16th Dec 20247:00 amRNSUpdate on Strategic Partnership in North America
21st Oct 20247:00 amRNSExecution of Agreement for North America
3rd Oct 20241:12 pmRNSUpdate on Licensing and Partnership Agreement
30th Sep 20247:00 amRNSInterim Results
16th Sep 20247:00 amRNSHolding(s) in Company
9th Sep 20247:00 amRNSCollaboration with Moffitt Cancer Center
25th Jul 20247:00 amRNSUpdate on Strategic Partnership in North America
18th Jul 20247:00 amRNSManufacturing Agreement with BBI Solutions
9th Jul 20247:00 amRNSIssue of Share Options in Lieu of Consultancy Fees
24th Jun 202412:42 pmRNSResult of AGM
17th Jun 20247:00 amRNSUpdate on North American Strategic Licensing MoU
3rd Jun 20247:00 amRNSNotice of Annual General Meeting
13th May 20247:00 amRNSHolding(s) in Company
30th Apr 20245:00 pmRNSTotal Voting Rights
30th Apr 20249:12 amRNSFinal results for the year ended 31 December 2023
23rd Apr 202411:20 amRNSHolding(s) in Company
2nd Apr 20247:00 amRNSLicensing and Partnership MoU for North America
26th Mar 20247:00 amRNSPlacing to raise £0.62 million
28th Sep 20237:00 amRNSInterim Results
21st Sep 20237:00 amRNSUpdate on Put Option with Conduit
19th Sep 20237:00 amRNSCompletion of Evaluation Programme with Bio-Techne
8th Sep 20237:03 amRNSExtension of and update on Put Option with Conduit
15th Aug 20237:00 amRNSUpdate on Put Option with Conduit
10th Aug 20237:00 amRNSExpansion of Research Agreement and CIZ1B Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.